(Pro³)-Gastric Inhibitory Polypeptide (human)
(Synonyms: (Pro3) Gastric Inhibitory Peptide, human) 目录号 : GA20278
一键复制产品信息
(Pro3)-Gastric Inhibitory Polypeptide (human)是一种人源葡萄糖依赖性促胰岛素多肽（GIP）的类似物，(Pro3)-Gastric Inhibitory Polypeptide可作为人GIP受体（hGIPR）的高效、稳定且特异性的完全激动剂，对人GIPR具有高结合亲和力(Ki/Kd=0.90nM)。
Cas No.:299898-52-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
(Pro3)-Gastric Inhibitory Polypeptide (human) is an analog of human glucose-dependent insulinotropic polypeptide (GIP), distinguished by the substitution of proline for glutamate at the third amino acid position. (Pro3)-Gastric Inhibitory Polypeptide acts as a potent, stable, and specific full agonist of the human GIP receptor (hGIPR), exhibiting high binding affinity (Ki/Kd=0.90nM)[1-2]. (Pro3)-Gastric Inhibitory Polypeptide is used in research related to obesity-associated diabetes and type 2 diabetes[3-4].
In vitro, using isolated human atrial preparations, simultaneous stimulation with (Pro3)-Gastric Inhibitory Polypeptide (100nM) and Tirzepatide (100nM) was performed. (Pro3)-Gastric Inhibitory Polypeptide attenuated the positive inotropic effect induced by Tirzepatide. (Pro3)-Gastric Inhibitory Polypeptide antagonized the GIP receptor-mediated enhancement of myocardial contractility[5]. COS-7 cells transiently transfected with the human GIP receptor were stimulated with (Pro3)-Gastric Inhibitory Polypeptide (4.7nM to 92nM) for 30 minutes. (Pro3)-Gastric Inhibitory Polypeptide acted as a full agonist with similar efficacy to native human GIP at the human GIP receptor[6].
In vivo, (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg) was administered via intraperitoneal injection once or twice daily to high-fat diet-induced obese diabetic mice for 48 days. (Pro3)-Gastric Inhibitory Polypeptide significantly improved glucose tolerance and insulin sensitivity, and reduced weight gain and hyperinsulinemia[7]. In fasted obese diabetic (ob/ob) mice, a single intraperitoneal injection of (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg) was administered. (Pro3)-Gastric Inhibitory Polypeptide significantly reduced the plasma insulin response 15 minutes after re-feeding, decreasing overall insulin release by 42%. In non-fasted ob/ob mice, a single intraperitoneal injection of (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg) ameliorated the basal hyperinsulinemia[8].
References:
[1] Rosenkilde MM, Lindquist P, Kizilkaya HS, et al. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology. Peptides. 2024 Jul;177:171212.
[2] McClean PL, Irwin N, Cassidy RS, et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1746-55.
[3] McClean PL, Gault VA, Irwin N, et al. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. Diabetes Obes Metab. 2008 Apr;10(4):336-42.
[4] Cassidy RS, Irwin N, Flatt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Biol Chem. 2008 Feb;389(2):189-93.
[5] Neumann J, Hofmann B, Kirchhefer U, et al. Tirzepatide increased force of contraction in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct;398(10):14451-14459.
[6] Sparre-Ulrich AH, Hansen LS, Svendsen B, et al. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol. 2016 Jan;173(1):27-38.
[7] McClean PL, Irwin N, Hunter K, et al. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol. 2008 Nov;155(5):690-701.
[8] Gault VA, O'Harte FP, Harriott P, et al. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003 Feb;46(2):222-30.
(Pro3)-Gastric Inhibitory Polypeptide (human)是一种人源葡萄糖依赖性促胰岛素多肽（GIP）的类似物，(Pro3)-Gastric Inhibitory Polypeptide可作为人GIP受体（hGIPR）的高效、稳定且特异性的完全激动剂，对人GIPR具有高结合亲和力(Ki/Kd=0.90nM)[1-2]。(Pro3)-Gastric Inhibitory Polypeptide可用于肥胖相关糖尿病和2型糖尿病的相关研究[3-4]。
在体外，在离体人心房标本中，加入(Pro3)-Gastric Inhibitory Polypeptide（100nM）和Tirzepatide（100nM）进行刺激。(Pro3)-Gastric Inhibitory Polypeptide可减弱Tirzepatide诱导的正性肌力效应，(Pro3)-Gastric Inhibitory Polypeptide能拮抗由葡萄糖依赖性促胰岛素多肽受体介导的心肌收缩力增强作用[5]。在瞬时转染了人GIP受体的COS-7细胞中，用(Pro3)-Gastric Inhibitory Polypeptide（4.7nM至92nM）刺激30分钟。(Pro3)-Gastric Inhibitory Polypeptide在人GIP受体上表现为与天然人GIP效能相似的完全激动剂[6]。
在体内，(Pro3)-Gastric Inhibitory Polypeptide（25nmol/kg）每天一次或两次腹腔注射，用于处理高脂饮食诱导的肥胖糖尿病小鼠，持续48天。(Pro3)-Gastric Inhibitory Polypeptide显著改善了葡萄糖耐量和胰岛素敏感性，并降低了体重增加和高胰岛素血症[7]。在禁食的肥胖糖尿病（ob/ob）小鼠中，单次腹腔注射(Pro3)-Gastric Inhibitory Polypeptide（25nmol/kg）。(Pro3)-Gastric Inhibitory Polypeptide显著降低了小鼠重新进食15分钟后的血浆胰岛素反应，总体胰岛素释放减少了42%。在非禁食的ob/ob小鼠中，单次腹腔注射(Pro3)-Gastric Inhibitory Polypeptide（25nmol/kg）可改善小鼠基础高胰岛素血症[8]。
| Cell experiment [1]: | |
Cell lines | COS-7 cells (African green monkey kidney fibroblast-like cell line) transiently transfected with human GIP receptor cDNA |
Preparation Method | Transfected COS-7 cells were assayed for cAMP accumulation. Cells were stimulated with species-specific (Pro3)-Gastric Inhibitory Polypeptide (4.7nM to 92nM) at the indicated concentration range for 30 minutes. |
Reaction Conditions | 4.7nM to 92nM; 30 minutes. |
Applications | (Pro3)-Gastric Inhibitory Polypeptide acted as a full agonist with similar efficacy as native human GIP at the human GIP receptor. |
| Animal experiment [2]: | |
Animal models | Obese diabetic (ob/ob) mice |
Preparation Method | Mice were fasted for 18 hours, then intraperitoneally administered a single dose of (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg). Following injection, the mice were allowed to re-feed for 15 minutes. Blood samples were collected at 0, 15, 30, 60, and 120 minutes post-injection for plasma insulin and glucose analysis. |
Dosage form | 25nmol/kg; i.p.; single injection. |
Applications | Administration of (Pro3)-Gastric Inhibitory Polypeptide significantly decreased the postprandial plasma insulin response in fasted mice, reducing the overall insulin release. (Pro3)-Gastric Inhibitory Polypeptide also lowered the basal hyperinsulinaemia in non-fasted mice. Accompanying changes in plasma glucose concentrations were minimal. |
References: | |
| Cas No. | 299898-52-5 | SDF | |
| 别名 | (Pro3) Gastric Inhibitory Peptide, human | ||
| 分子式 | C226H338N60O64S | 分子量 | 4951.6 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 202 μL | 1.0098 mL | 2.0195 mL |
| 5 mM | 40.4 μL | 202 μL | 403.9 μL |
| 10 mM | 20.2 μL | 101 μL | 202 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet